1
40
2
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Treatment of Symptoms in Children with Q3 Conditions Scoping Review Results
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1046/j.1365-2788.2002.00404.x" target="_blank" rel="noreferrer noopener">http://doi.org/10.1046/j.1365-2788.2002.00404.x</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Sleep problems and daytime problem behaviours in children with intellectual disability
Publisher
An entity responsible for making the resource available
Journal of Intellectual Disability Research
Date
A point or period of time associated with an event in the lifecycle of the resource
2002
Subject
The topic of the resource
children; Rehabilitation; adolescents; Neurology; disorders; Education & Educational Research; Genetics & Heredity; Neurosciences &; Psychiatry; handicapped-children; disturbance; challenging behavior; adults; community-based sample; daytime problem behaviour; difficulties; severe learning-disabilities; sleep problem; behavior; breathing difficulties; sleep disturbance; urinary incontinence; Rett syndrome; tuberous sclerosis; trajectory; characteristics; intellectual disability
Creator
An entity primarily responsible for making the resource
Didden R; Korzilius H; van Aperlo B; van Overloop C; de Vries M
Description
An account of the resource
BACKGROUND: Sleep problems are common among children with intellectual disability (ID). METHOD: The present study assessed the prevalence of severe sleep problems in a sample of children (n=286) with mild to profound ID who lived at home with their parents(s) in the Netherlands. It also explored relationships between severe sleep problems, and family and child variables. Demographic information, data on children's sleep behaviours and parent variables were collected using questionnaires. RESULTS: Severe settling problems, night waking and early waking were present in 4.2%, 10.8% and 4.2% of cases, respectively; 16.1% of children had at least one type of sleep problem. Children with a severe sleep problem had more severe levels of ID, used medication more often, had a greater frequency of epilepsy, were younger, had a greater frequency of cerebral palsy, and showed more daytime drowsiness and daytime napping than children without a severe sleep problem. Furthermore, children with a severe sleep problem showed more severe levels of daytime problem behaviours; for example, aggression, non-compliance and hyperactivity. CONCLUSION: The results of the present study are discussed with regard to the assessment and treatment of sleep problems in children with ID.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1046/j.1365-2788.2002.00404.x" target="_blank" rel="noreferrer noopener">10.1046/j.1365-2788.2002.00404.x</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2002
Adolescents
adults
Behavior
breathing difficulties
challenging behavior
characteristics
Children
community-based sample
daytime problem behaviour
de Vries M
Didden R
difficulties
Disorders
disturbance
Education & Educational Research
Genetics & Heredity
handicapped-children
Intellectual Disability
Journal Of Intellectual Disability Research
Korzilius H
Neurology
Neurosciences &
Psychiatry
Rehabilitation
Rett syndrome
severe learning-disabilities
sleep disturbance
sleep problem
Trajectory
Tuberous Sclerosis
urinary incontinence
van Aperlo B
van Overloop C
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Treatment of Symptoms in Children with Q3 Conditions Scoping Review Results
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.3310/hta16400" target="_blank" rel="noreferrer noopener">http://doi.org/10.3310/hta16400</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The use of Melatonin in children with Neurodevelopmental Disorders and impaired Sleep: a randomised, double-blind, placebo-controlled, parallel study (MENDS)
Publisher
An entity responsible for making the resource available
Health Technology Assessment
Date
A point or period of time associated with an event in the lifecycle of the resource
2012
Subject
The topic of the resource
insomnia; Health Care Sciences & Services; autism spectrum disorders; controlled-trial; exogenous melatonin; handicapped-children; improves sleep; onset; phase; rett-syndrome; serum melatonin; syndrome; young-adults; sleep disturbance/disorders; neurodevelopmental disorders; pharmacologic intervention; melatonin
Creator
An entity primarily responsible for making the resource
Appleton R E; Jones A P; Gamble C; Williamson P R; Wiggs L; Montgomery P; Sutcliffe A; Barker C; Gringras P
Description
An account of the resource
Background: Difficulties in initiating and maintaining sleep are common in children with neurodevelopmental disorders. Melatonin is unlicensed in children yet widely prescribed for sleep problems. Objective: To determine whether or not immediate-release melatonin is beneficial compared with placebo in improving total duration of night-time sleep in children with neurodevelopmental problems. Design: Randomised, double-blind, placebo-controlled, parallel study. Setting: Hospitals throughout England and Wales recruited patients referred by community paediatricians and other clinical colleagues. Participants: Children with neurodevelopmental problems aged from 3 years to 15 years 8 months who did not fall asleep within 1 hour of lights out or who had <6 hours of continuous sleep. Before randomisation, patients meeting eligibility criteria entered a 4- to 6-week behaviour therapy period in which a behaviour therapy advice booklet was provided. Sleep was measured using sleep diaries and actigraphy. After this period the sleep diaries were reviewed to determine if the sleep problem fulfilled the eligibility criteria. Eligible participants were randomised and followed for 12 weeks. Interventions: Melatonin or placebo capsules in doses of 0.5 mg, 2 mg, 6mg and 12 mg for a period of 12 weeks. The starting dose was 0.5 mg and the dose could be escalated through 2 mg and 6 mg to 12 mg during the first 4 weeks, at the end of which the child was maintained on that dose. Main outcome measures: The primary outcome was total night-time sleep time (TST) calculated using sleep diaries at 12 weeks compared with baseline. Secondary outcome measures included TST calculated using actigraphy data, sleep-onset latency (SOL) (time taken to fall asleep), sleep efficiency, Composite Sleep Disturbance Index score, global measure of child's sleep quality, Aberrant Behaviour Checklist, Family Impact Module of the Pediatric Quality of Life Inventory (PedsQL (TM)), the Epworth Sleepiness Scale, number and severity of seizures and adverse events. Salivary melatonin concentrations and association of genetic variants with abnormal melatonin production were also investigated. Results: A total of 275 children were screened to enter the trial; 263 (96%) children were registered and completed the 4- to 6-week behaviour therapy period and 146 (56%) children were randomised, of whom 110 (75%) contributed data for the primary outcome. The difference in TST time between the melatonin and placebo groups adjusted for baseline was 22.43 minutes [95% confidence interval (Cl) 0.52 to 44.34 minutes; p = 0.04] measured using sleep diaries. A reduction in SOL, adjusted for baseline, was seen for melatonin compared with placebo when measured by sleep diaries (-37.49 minutes, 95% CI -55.27 to -19.71 minutes; p < 0.0001) and actigraphy (-45.34 minutes, 95% CI -68.75 to -21.93 minutes; p=0.0003). There were no significant differences between the two groups in terms of the reporting of adverse events. The results of other secondary outcomes favoured melatonin but were not statistically significant. Conclusions: On average, the children treated with melatonin slept 23 minutes longer than those in the placebo group; however, the upper limit of the confidence interval was less than 1 hour, the minimum clinically worthwhile difference specified at the outset of the trial. Melatonin is effective in reducing SOL in children with neurodevelopmental delay by a mean of 45 minutes; a value of 30 minutes was specified a priori to be clinically important. Future studies should be conducted over longer periods and directly compare different formulations of melatonin with conventional hypnotic and sedative medications. It would also be important to study groups of children with specific neurological disorders. Trial registration: Current Controlled Trials ISRCTN05534585.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.3310/hta16400" target="_blank" rel="noreferrer noopener">10.3310/hta16400</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2012
Appleton R E
autism spectrum disorders
Barker C
CONTROLLED-TRIAL
exogenous melatonin
Gamble C
Gringras P
handicapped-children
Health Care Sciences & Services
Health Technology Assessment
improves sleep
insomnia
Jones A P
melatonin
Montgomery P
neurodevelopmental disorders
onset
pharmacologic intervention
phase
rett-syndrome
serum melatonin
sleep disturbance/disorders
Sutcliffe A
Syndrome
Wiggs L
Williamson P R
young-adults